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1. ZUSAMMENFASSUNG 
Kurz nach Unterstellung des Mephedron, eine Cathinon-verwandte Designer-Droge, unter das 
Betäubungsmittelgesetz, wurde Naphyron (1-Naphthalen-2-yl-2-pyrrolidin-1-yl-pentan-1-on; 
Naphthylpyrovaleron, β-Naphyron) als Ersatz gehandelt. Inzwischen ist auch Naphyron dem 
Betäubungsmittelgesetz unterstellt. Daher war das Ziel dieser Dissertation die Identifizierung 
der Metaboliten von Naphyron in Rattenurin mittels Gaschromatographie-
Massenspektrometrie (GC-MS) oder Flüssigchromatographie-Hochauflösender-Tandem-
Massenspektrometrie (LC-HR-MS/MS)-Techniken. Die Hauptschritte im Metabolismus von 
Naphyron waren wie folgt: Oxidation des Pyrrolidinrings zum entsprechenden Lactam, 
Hydroxylierung der Propylseitenkette und des Naphthylrings, Abbau des Pyrrolidinrings zum 
primären Amin oder Kombinationen dieser Schritte. Die mittels GC-MS identifizierten Phase 
I Metaboliten konnten unter Verwendung der LC-HR-MS/MS bestätigt werden. Zusätzlich 
konnten drei Phase II-Metaboliten (Glucuronide) identifiziert werden. Ein weiterer Teil dieser 
Arbeit bestand in der Identifizierung der humanen Cytochrom P450 (CYP) Isoenzyme der 
Leber, die den initialen Schritt im Metabolismus von Naphyron katalysieren. Unter den zehn 
wichtigsten humanen CYP-Enzymen waren nur die Isoenzyme CYP2C19 und CYP2C9 in der 
Lage die Hydroxylierung am Naphthylring in deutlichem Ausmaß zu katalysieren.  
 
2. SUMMARY 
Rapidly after scheduling mephedrone, which was one the first cathinone-derived designer 
drugs to be brought on the drugs of abuse market, naphyrone (1-naphthalen-2-yl-2-pyrrolidin-
1-yl-pentan-1-one; naphthylpyrovalerone, β-naphyrone) appeared as replacement. Currently 
naphyrone itself was scheduled. Therefore, the aim of this study was to study its in vivo and 
in vitro metabolic fate. By means of gas chromatography-mass spectrometry (GC-MS) and 
liquid chromatographic-high-resolution tandem-mass spectrometric (LC-HR-MS/MS) 
techniques, the following metabolic steps could be observed in vivo: degradation to the 
primary amines after opening of the pyrrolidine ring, oxidation of the pyrrolidine ring to the 
corresponding lactam, hydroxylation of the propyl side chain and the naphthyl ring, and 
combinations of these steps. In vitro, human cytochrome P450 (CYP) isozymes CYP2C19  
and CYP2C9 were identified to catalyze the hydroxylation of the naphthyl ring.  
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3. INTRODUCTION 
In recent years, a wide range of new cathinone designer drugs appeared on the drug of abuse 
market. They became popular as so called “legal highs”. The probably most important 
representative is mephedrone, which was scheduled in April 2010.[
1-3
] Since then, a dramatic 
increase of legal alternatives distributed online and sold as “bath salts” or “plant food” and 
labeled not for “human consumption” to evade drug legislation was observed.[2,4,5] These 
substances are consumed especially amongst young adults, homosexual men, and club 
people.[
6-8
] 
However, there is only little information available about their pharmacological and 
toxicological risks and harmful long-term effects [
2,4,5
] because such drugs are marketed 
without any safety testing. It seems that the increased recreational use of legal highs is due to 
the widespread availability on the Internet and the advantages of being cheap and steadily 
available. As earlier studies have shown, this implicates the consumers that these new 
substitutes were pure, safe, and carrying a low risk for health.[
1
] However, recent research 
articles have shown that most of the products contain a mixture of different cathinones.[
1
] 
Consequently, the consumers often do not know exactly what kind of compound they are 
taking and how to dose it.  
 
3.1 Chemical structure of naphyrone and its similarity to mephedrone 
Naphyrone (1-naphthalen-2-yl-2-pyrrolidin-1-yl-pentan-1-one; naphthylpyrovalerone, β-
naphyrone) is a cathinone-derived designer drug and was marketed as replacement for the 
synthetic cathinone derivative mephedrone. Naphyrone is sold in preparations such as NRG-1, 
Energy-1, or O-2482 and available online as so-called bath salt or plant food.[
1,5
] Its chemical 
structure in comparison to mephedrone is depicted in Figure 1. 
 
 
 
Figure 1. Chemical structure of naphyrone. The structural part common with mephedrone is 
highlighted in red. 
O
N
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3.2 Effects of naphyrone 
Naphyrone inhibits the re-uptake of monoamines by inhibiting the serotonin, dopamine, and 
norepinephrine transporters with an approximately 10-fold higher potency than cocaine.[
5
] 
Entactogenic and sympathomimetic effects, such as feelings of empathy, increased energy, 
openness, and talkativeness are desired.[
2,2,4,4,5,5
] However, there is also a wide range of 
adverse effects such as cardiovascular risk, anxiety, hallucinations, insomnia, and 
nervousness.[
2,4,5
] According to reports found in online forums, the feeling of euphoria and 
high mood is supposed to be less after taking naphyrone in comparison to mephedrone and the 
rate of unwanted side effects is supposed to be higher. 
Naphyrone showed a much higher potency with increased risk of overdose when used in 
amounts similar to mephedrone.[
5
] In general, the long-term effects of pyrrolidinophenones 
were not clearly defined. But especially naphyrone seemed to be even more harmful than its 
related derivatives, not least because of its naphthalene ring and the associated possible risk of 
carcinogenicity.[
5
] 
 
3.3 Former publications on naphyrone 
One publication is available presenting data on the metabolism of naphyrone by human liver 
microsomes. As with this approach only cytochrome P450 (CYP)-catalyzed metabolites could 
be formed, important reactions such as reactions catalyzed by alcohol or aldehyde 
dehydrogenase (ADH/ALDH) and the phase II reactions were missing.[
9
] A case report has 
been published about a patient suffering from acute sympathomimetic toxicity after ingestion 
of naphyrone.[
5
] 
 
3.4 Aim of the presented work 
The aim of the present study was the identification of naphyrone and its metabolites in rat 
urine using GC-MS and LC-HR-MS/MS. Additionally, the CYPs responsible for the initial 
metabolic step were identified. 
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4. EXPERIMENTAL PROCEDURES / MATERIAL AND METHODS 
4.1 Chemicals and reagents 
Naphyrone hydrochloride was obtained before scheduling from LGC (Luckenwalde, 
Germany), Isolute HCX cartridges (130 mg, 3 ml) from Biotage (Uppsala, Sweden) and all 
other chemicals and reagents from VWR, Darmstadt (Germany) and they were of analytical 
grade. 
 
4.2 Urine samples 
The investigations were performed using urine of male Wistar rats (Charles River, Sulzfleck, 
Germany) for toxicological diagnostic reasons according to the corresponding German law. 
They were administered a single 20 mg/kg body mass dose of naphyrone for identification of 
the metabolites. Urine was collected separately from the feces over a 24 h period. 
 
4.3 Sample preparation 
4.3.1 Sample preparation for phase I metabolism studies 
The sample preparation was the same as described previously.[
10
] Briefly, a 2.0 ml portion of 
urine was adjusted to pH 5.2 and incubated at 56°C for 1.5 h with glucuronidase (EC No. 
3.2.1.31, Merck) and arylsulfatase (EC No. 3.1.6.1). Afterwards, the urine was solid phase 
extracted (SPE) using HCX columns, derivatized by acetylation [
11
] and dissolved in 50 µl of 
methanol prior to injection into the GC-MS system.  
4.3.2 Sample preparation for phase II metabolism studies 
For elucidating the formation of glucuronides and sulfates, 200 µl of urine were mixed with 
200 µl of acetonitrile for urine dilution and desalinization, centrifuged at14.000g for 5 min 
and the supernatant was transferred into an autosampler vial. A 10 µl aliquot of this solution 
was injected into the LC system. 
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4.4 Enzymatic Studies 
4.4.1 Microsomal Incubations 
The microsomal incubations were the same as described previously.[
10
] Briefly, incubations 
were performed with HLM, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, 
CYP2D6, CYP2E1, CYP3A4, or CYP3A5 at a substrate concentration of 25 µM for 30 min 
at 37°C.  
 
4.5 GC-MS and LC-HR-MS/MS settings 
4.5.1 GC-MS apparatus for metabolism studies  
The extracts were analyzed using the same GC-MS setup as described previously.[
10
] Briefly, 
a Hewlett Packard (HP, Agilent, Waldbronn, Germany) 5890 Series II gas chromatograph 
combined with an HP 5972A MSD mass spectrometer and an HP MS ChemStation (DOS 
series) with HP G1034C software version C03.00. a HP-1 capillary (12 m x 0.2 mm I.D.) and 
an injection port temperature of 280°C with a column temperature, programmed from 100-
310°C at 15°/min, initial time 3 min, final time 8 min were used. The MS was operated in 
full-scan mode (m/z 50-550).  
4.5.2 LC-HR-MS/MS apparatus for identification of phase I and II metabolites and 
for analysis of microsomal incubations 
Naphyrone and its phase I and II metabolites were analyzed using a ThermoFisher Scientific 
(TF, Dreieich, Germany) Accela LC system consisting of a degasser, a high pressure 
quaternary pump and a HTC PAL autosampler (CTC Analytics AG, Zwingen, Switzerland), 
coupled to a TF Q-Exactive system equipped with heated electrospray ionization II (HESI-II) 
source. The LC conditions were the same as described previously.[
10
] The MS settings were 
as follows. The mass spectrometer was operated in the positive ionization mode. The 
ionization voltage, capillary temperature, vaporizer temperature, sheath gas, and auxiliary gas 
were set to 3.0 kV, 380°C, 350°C, 60 psi and 20 au, respectively. The mass spectrometer 
acquired full-scan data (m/z 50 – 750) at a resolution of 70,000 (full width at half maximum 
(FWHM) at m/z 200) and a data-dependent MS/MS scan at a resolution of 35,000 (FWHM at 
m/z 200). The parent ion was selected in the quadrupole (isolation window 1.5 u and 
subsequently fragmented in the higher energy collision dissociation (HCD) cell using  
5 RESULTS AND DISCUSSION 
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normalized collision energy of 35 eV. A full scan (m/z 50 - 750) of all fragmented ions 
originating from the parent ion was performed.  
 
5. RESULTS AND DISCUSSION 
5.1 Identification of naphyrone metabolites 
The identification of the metabolites of naphyrone in rat urine resulted from full-scan EI after 
SPE, acetylation and GC separation. Analyzing one extract without acetylation allowed 
discriminating between N-acetyl derivatives formed by metabolism and N-acetyl derivatives 
formed by derivatization. 
In accordance to common fragmentation rules and in correlation to the representative 
fragmentation of the unchanged naphyrone molecule, the postulated structures of the 
naphyrone metabolites could be detected in the EI mode.[
12,13
] The EI mass spectra, the main 
fragmentation patterns and corresponding structures of naphyrone and its acetylated 
metabolites are depicted in Figure 2 and 3, ranged after the ascending gas chromatographic 
retention indices (RI). 
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Figure 2. EI mass spectra, gas chromatographic retention indices (RI) of naphyrone and its 
metabolites arranged according to their RI. 
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Figure 2 continued 
100 
100 
100 
100 
100 
5 RESULTS AND DISCUSSION 
___________________________________________________________________________ 
 
13 
 
 
Figure 2 continued 
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Figure 3. Proposed structures and predominant fragmentation patterns of naphyrone and 
its metabolites. The numbers correspond to them in Figure 2. The wavy bonds symbolize 
that a definite assignment to a particular isomer was not possible. 
 
5.2 Proposed fragmentation patterns for identification of the phase I metabolites 
by GC-MS 
In consensus with previously published data on the fragmentation of the underivatized parent 
compound the expected fragmentation patterns of naphyrone metabolites could be discussed 
as follows.[
3,5
] 
In the EI mass spectrum no. 1 in Figure 2 the fragmentation patterns of the unchanged parent 
compound are shown. A typical fragmentation step between the keto moiety and the tertiary 
amine is the detected α-cleavage. The base peak of this spectrum is represented by an 
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immonium ion at m/z 126. Optional α-cleavage at this position (between position 1 and 2) 
provides a naphthoyl ion at m/z 155, which is both stabilized by the mesomerism of the 
naphthyl part and of the carbonyl moiety. A naphthyl ion at m/z 127 indicates a subsequent 
CO loss. Another possibility for α-cleavage shows the ion at m/z 238, which is the result of 
the cleavage between the carbonyl group and the aliphatic side chain (between position 2 and 
3). 
Further, a combination of α-cleavage between position 1 and 2, followed by cleavage in the 
aliphatic side chain between position 3 and 4 yielded an ion at m/z 96. The ion at m/z 84 is the 
result of the loss of a methyl group from the fragment ion at m/z 96. Via α-cleavage between 
position 1 and 2 corresponding to the parent compound in all acetylated metabolites the 
immonium ions at m/z 114 (nos. 2, 4, 7), 140 (nos. 3, 8, 10), 126 (nos. 5, 6), 198 (no. 9), or 
184 (nos. 11, 12) were formed. In all of the following discussed spectra these ions always 
provide the base peak of the spectrum. The only exception can be seen in spectra nos. 2, 4, 7. 
In these spectra the ion at m/z 72 represents the base peak, which is the result of α-cleavage 
between position 1 and 2 leading to the ion at m/z 114 (in analogy to the formation of the ions 
representing the base peak) followed by a neutral loss of an acetyl part performing the base 
peak ion at m/z 72.  
In accordance to the underivatized parent compound the naphthoyl ion at m/z 155 (nos. 2, 3, 
9) indicates the unchanged naphthyl part. The appearance of the ions at m/z 213, 171, and 143 
indicate the presence of the acetylated hydroxyl groups in the naphthyl part. A neutral loss of 
the acetyl part (distinctive shift of 42 units) leads to the ion at m/z 171, followed by the 
subsequent loss of the CO part yielding an ion at m/z 143 (nos. 4-8 and 10-12).  
These metabolites carrying acetylated hydroxyl groups in the naphthyl part implicate the 
existence of at least two positional isomers. However, it must be mentioned that the exact 
position of the hydroxyl group in the naphthyl part cannot be deduced from the fragmentation 
patterns. 
According to the distinctive 14 u shift (m/z 126 to 140) observed for the metabolites 
depicted in spectra nos. 3, 8, and 10, an ion at m/z 140 can be detected but not an additional 
neutral loss of an acetyl group or acetic acid. Consequently, theses metabolites implicate the 
existence of an oxo group in the propyl-pyrrolidine moiety. The fragment ion at m/z 140 leads 
after further cleavage (between position 2 and 3) to the fragment ion at m/z 98 representing 
the lactam part. However, it must me mentioned that the exact position of the oxo moiety in 
the pyrrolidino-oxo metabolites cannot be deduced from the presented fragmentation 
patterns.[
14
] 
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In spectrum no. 9 an absence of the distinctive 14 u shift (m/z 126 to 140) could be 
observed, though the ion at m/z 98 representing the lactam structure could be detected. 
However, based on the non-metabolic acetylation of the hydroxyl group in the propyl side 
chain the presence of m/z 198, 156, and 138 provides the recommended structure. In addition, 
the characteristic shift of 60 units from m/z 198 to 138 distinctively a neutral loss of acetic 
acid could be observed in spectrum no. 9, further in spectra nos. 11 and 12 (m/z 184 to 124). 
Therefore, these discussed fragmentation patterns of spectra nos. 9, 11, and 12 suppose the 
metabolic hydroxylation of the propyl side chain. However, it must be mentioned again that it 
is not possible to deduce the exact position of the hydroxyl group in the propyl side chain 
from the fragmentation patterns.  
The fragmentation patterns of spectra nos. 2, 4, and 7 implicate the existence of 
metabolites containing a primary amine. Due to these non-metabolically acetylated 
metabolites a shift of 42 u distinctively the neutral loss of an acetyl part from the fragment ion 
at m/z 114 to 72 could be observed, after cleavage of the pyrrolidine part. The postulated 
metabolite structures concerning the propyl-pyrrolidine part were in accordance to previously 
published metabolism studies of the pyrrolidinophenone-type designer drugs containing the 
same structural part, such as MDPV and PVP.[
14,15
] 
Due to these mass spectra, the following phase I reactions could be observed: N,N-bis-
dealkylation (metabolite no.2 in Figure 3), oxidation (3), hydroxylation and N,N-bis-
dealkylation (4, 7), naphthyl hydroxylation (5, 6), naphthyl hydroxylation and oxidation (8, 
10), alkyl hydroxylation and oxidation (9) and naphthyl/alkyl bis-hydroxylation (11, 12). 
 
5.3 Confirmation of phase I metabolites and identification of phase II metabolites 
by LC-HR-MS/MS 
The GC-MS-identified phase I metabolites of naphyrone could be verified using the LC-HR-
MS/MS procedure. Furthermore, glucuronides of some phase I metabolites (nos. 5, 6, 8, and 
10-12) were additionally identified. The calculated exact masses of the protonated and 
underivatized naphyrone and its corresponding phase I and II metabolites are shown in Table 
1.  
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Table 1. List of naphyrone and its phase I and II metabolites, the measured exact masses of 
their protonated molecule and representative fragment ions, the corresponding calculated 
exact masses, and the suggested elemental compositions. 
Metabolites and characteristic ions [m/z] Calculated exact masses [u] Elemental compositions 
naphyrone, 282.1851 
211.1116 
141.0967 
126.1278 
282.1858 [M+H]+ 
211.1117 
141.0699 
126.1283 
C19H24NO 
C15H15O 
C11H9 
C8H16N 
N,N-bis-dealkyl naphyrone, 228.1376 
210.1276 
168.0806 
141.0698 
228.1388 [M+H]+ 
210.1283 
168.0813 
141.0704 
C15H18NO 
C15H16N 
C12H10N 
C11H9 
oxo naphyrone, 296.1638 
141.0696 
140.1069 
98.0603 
296.1650 [M+H]+ 
141.0699 
140.1070 
98.0600 
C19H22NO2 
C11H9 
C8H14NO 
C5H8NO 
hydroxy-naphthyl-N,N-bis-dealkyl naphyrone, 244.1332 
226.1225 
183.0679 
157.0647 
244.1337 [M+H]+ 
226.1232 
183.0684 
157.0653 
C15H18NO2 
C15H16NO 
C12H9NO 
C11H9O 
hydroxy-naphthyl naphyrone, 298.1797 
227.1065 
157.0647 
126.1277 
298.1807 [M+H]+ 
227.1072 
157.0648 
126.1283 
C19H24NO2 
C15H15O2 
C11H9O 
C8H16N 
hydroxy-naphthyl-oxo naphyrone, 312.1591 
227.1065 
157.0647 
140.1069 
312.1600 [M+H]+ 
227.1072 
157.0648 
140.1070 
C19H22NO3 
C15H15O2 
C11H9O 
C8H14NO 
hydroxy-alkyl-oxo naphyrone, 312.1589 
270.1122 
252.1017 
224.1068 
312.1600 [M+H]+ 
270.1130 
252.1024 
224.1075 
C19H22NO3 
C16H16NO3 
C16H14NO2 
C15H14NO 
hydroxy-naphthyl-hydroxy-alkyl naphyrone, 314.1745 
227.1065 
157.0647 
142.1226 
314.1756 [M+H]+ 
227.1072 
157.0648 
142.1226 
C19H24NO3 
C15H15O2 
C11H9O 
C8H16NO 
hydroxy-naphthyl naphyrone glucuronide, 474.2121 
298.1798 
227.1064 
157.0647 
474.2128 [M+H]+ 
298.1807  
227.1072 
157.0648 
C25H32NO8 
C19H24NO2 
C15H15O 
C11H9O2 
hydroxy-naphthyl-oxo naphyrone glucuronide, 488.1916 
312.1592 
157.0647 
140.1065 
488.1920 [M+H]+ 
312.1600  
157.0648 
140.1070 
C25H30NO9 
C15H15O2 
C11H9O 
C8H14NO 
hydroxy-naphthyl-hydroxy-alkyl naphyrone glucuronide, 490.2069 
314.1747 
227.1064 
142.1225 
490.2077 [M+H]+ 
314.1756  
227.1072 
142.1226 
C25H32NO9 
C19H24NO3 
C15H15O2 
C8H16NO 
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5.4 Proposed metabolic pathways 
From the above-described metabolites, the following partly overlapping metabolic pathways 
for naphyrone in rats could be postulated: hydroxylation of the pyrrolidine ring followed by 
dehydrogenation to analogous lactams (nos. 3 and 8-10), hydroxylation of the aliphatic side 
chain (9) or the naphthyl ring system (nos. 4-8, and 10), or both combined (nos. 11 and 12), 
and last-mentioned, degradation of the pyrrolidine ring to the corresponding primary amines 
(nos. 2, 4, and 7). In Figure 4, arrows are indicating areas of described metabolic reactions. 
 
 
 
Figure 4. Structures of naphyrone with arrows indicating the areas of the described 
metabolic reactions. 
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5.5 Initial CYP screening 
In order to identify the CYP enzymes, which were able to catalyze the hydroxylation at the 
naphthyl part of the molecule, an initial screening with the ten most abundant human hepatic 
CYPs was performed. Exclusively CYP2C19 and CYP2C9 were capable of catalyzing the 
hydroxylation of the naphthyl part. 
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6. CONCLUSIONS 
 
The presented study revealed that naphyrone is extensively metabolized in rats and that the 
initial human metabolic reaction should be the hydroxylation of the naphthyl part of the 
molecule. This reaction could be shown to be catalyzed by CYP2C19 and CYP2C9, which 
may lead to severe interactions after co-ingestion of respective CYP inhibitors or in the case 
of a slow metabolizing phenotype. Due to the enormous increase of new Designer Drugs and 
the corresponding health risks, it is an important issue to identify and to study new emerged 
substances. In summary, this study could contribute to identification and detection of the 
recreational drug naphyrone by elucidating its metabolic pathways in both species. Supposing 
similar kinetic processes in rats and humans, this study could serve as a basis for developing 
suitable screening strategies for detection of a naphyrone intake. This will be investigated in a 
further study. 
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8. ABBREVIATIONS 
 
EI    Electron Ionization 
 
FWHM  full width at half maximum 
 
GC-MS   gas chromatography- mass spectrometry 
 
HCD   Higher-energy C-trap dissociation 
 
LC-HR-MS  liquid chromatography- high resolution- mass spectrometry 
 
LC-MS  liquid chromatography- mass spectrometry 
 
LC-MS
n
  liquid chromatography- ion trap mass spectrometry  
 
m/z   mass-to-charge ratio 
 
RI   Gas Chromatographic Retention Index 
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